DNAe is developing LiDia-SEQ™, a direct-from-specimen platform that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians.
Location: United States, California, London
Employees: 51-200
Total raised: $38.54M
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Excel Vent... | excelvm.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.11.2015 | - | $38.54M | - |
Mentions in press and media 3
| Date | Title | Description |
| 02.07.2021 | CureVac gains COO and hands Florian von der Mülbe new assignment in the midst of Covid-19 vaccine troubles; As Ken Frazier retires, Merck hires chief strategy officer | Malte Greune → Aiming to bounce back and trying to accentuate the positive after its mRNA Covid-19 vaccine took a major pratfall, CureVac is shaking things up by bringing in Malte Greune as COO and giving new responsibi... |
| 18.10.2017 | Mainstream telehealth needs vendors to address pain points | Many of us are impatient for a future where telehealth reduces our visits to health professionals. Whether you are geographically isolated, tired of waiting hours in a waiting room for an overdue appointment or simply have felt the pain of ... |
| 02.11.2015 | DNAe Secures £25M Bank Facility with Citibank | DNAe, a London, UK-based developer of semiconductor DNA sequencing technology, secured a bank facility of £25m ($38m) with Citibank. The company will use the capital, which follows an internal fundraising that raised $24m in January 2015 to... |